Sttr phase i: a therapeutic molecule for covid-19
Ended Project Grant Awarded Last action
- Award ID
- 2035422
- Recipient
-
Eradivir Inc. UEI QGDJNUMU9VR6
- Awarding agency
-
Division of Industrial Innovation
National Science Foundation
- Obligated
- $256,000
Award facts
- Assistance listing
- 47.041 Engineering
- Completion date
- Place of performance
- West Lafayette, IN, USA
Award details come from USAspending.gov.
About this award
Eradivir Inc. received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation to develop a therapeutic molecule for COVID-19. Under the grant, awarded February 15, 2021 for the period through January 31, 2022, Eradivir will conduct research at its facilities in West Lafayette, Indiana under the NSF's Engineering program (CFDA #47.041). The Engineering program seeks to improve quality of life and economic strength through fostering innovation in engineering research and education. Specifically, the company will use the grant funding to advance development of a novel therapeutic to treat COVID-19 infections.
Quick answers
Who received award 2035422?
2035422 was awarded to Eradivir Inc. by Division of Industrial Innovation (National Science Foundation) on February 15, 2021.
How much is award 2035422 worth?
$256,000 has been obligated on 2035422.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award